Blood-brain barrier drug delivery

InSightec and Cordance Medical are named corporate organizations in the field, while research activity includes the Chinese Academy of Sciences CAS, Zhejiang University and Harvard University. The work spans focused-ultrasound opening, nanocarriers and receptor-mediated transport. The organizations listed here are examples from the available data, not a ranked list of commercial suppliers.

Cordance Medical, Manifold Bio and Longeviti Neuro Solutions LLC are identified as startups working on BBB delivery. Cordance Medical focuses on ultrasound systems that use physiological signals to assess barrier opening; Manifold Bio works on receptor-mediated transcytosis strategies; and Longeviti Neuro Solutions LLC is associated with ultrasound-mediated opening using sonolucent cranial implants.

The Chinese Academy of Sciences CAS, Chitkara University and Capital Medical University are among the prominent research organizations in the available data. Their work includes nanocarriers, engineered vesicles and brain-targeted formulations. Other active groups include Harvard University, Zhejiang University and the University of Maryland College Park, with research spanning focused ultrasound and receptor-mediated delivery.

The data records 51 grants totaling $31,627,867 since 2020 and 22 funding rounds totaling $58,295,835,794. These figures include entries that may reflect broader institutional or corporate activity rather than dedicated BBB-delivery financing. Treat the round total with particular caution when assessing funding specifically available to BBB drug-delivery developers.

California Institute of Technology leads the listed patent holders with 4 patents. InSightec, Cordance Medical and MEPSGEN each have 3 listed patents. These counts identify the leading holders in the provided patent-holder data; they do not establish the scope, status or commercial value of each organization’s intellectual property.

No: patent activity declined by 46% over the last 12 months compared with the previous 12 months, while 97 patents are recorded in the 24-month window. This contrasts with publication activity, which grew by 37.5% in the last 12 months. The divergence suggests continued research momentum alongside a softer recent patenting trend.

In October 2026, researchers reported an Angiopep-2-functionalized copper-manganese nanoplatform for glioma therapy and an EphB1-mediated transient opening approach paired with a ferritin-based Alzheimer’s therapy. News in October 2026 also highlighted particle-size effects on brain and tumor delivery. These developments combine transport engineering with efforts to control targeting and therapeutic effect.

The five main approaches are receptor-mediated transcytosis, nanocarriers and vesicles, physical barrier opening, molecular optimization and prodrugs, and cell-mediated delivery. Transcytosis and carriers aim to transport cargo across the intact barrier; ultrasound can temporarily increase permeability. Each route faces different trade-offs in targeting, safety, payload suitability and control of exposure.

The largest listed applications are neurodegenerative diseases, with 2,285 documents, and brain tumors, with 2,146. Other neurological disorders account for 1,137 documents, while CNS genetic and metabolic disorders account for 143. These categories reflect research and patent activity, including work on Alzheimer’s disease, glioma and other conditions.

The United States leads with 7,391 documents, followed by China with 5,985 and India with 2,917. The United Kingdom and Germany are also among the leading countries in the available data. These figures indicate where recorded activity is concentrated; they do not measure the quality or commercial maturity of each country’s work.